@article{9b8bda8f63ac4e38b5b4f406b467ce6e,
title = "Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature",
abstract = "Use of ustekinumab in Crohn's disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn's disease, who developed an anaplastic large cell T cell lymphoma during treatment with ustekinumab.",
keywords = "Ustekinumab, lymphoma, Crohn's disease, INFLAMMATORY-BOWEL-DISEASE, MAINTENANCE THERAPY, TERM SAFETY, CANCER-RISK, INDUCTION",
author = "Smeets, {Fabienne G. M.} and Liedorp, {Paulien R.} and {van der Poel}, Marjolein and Miclea, {Razvan L.} and Masclee, {Ad A. M.} and Marieke Pierik",
note = "Publisher Copyright: Copyright {\textcopyright} 2019 European Crohn's and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2019",
month = nov,
doi = "10.1093/ecco-jcc/jjz084",
language = "English",
volume = "13",
pages = "1470--1473",
journal = "Journal of Crohn's & Colitis",
issn = "1873-9946",
publisher = "Oxford University Press",
number = "11",
}